JP2021518384A5 - - Google Patents

Info

Publication number
JP2021518384A5
JP2021518384A5 JP2020550176A JP2020550176A JP2021518384A5 JP 2021518384 A5 JP2021518384 A5 JP 2021518384A5 JP 2020550176 A JP2020550176 A JP 2020550176A JP 2020550176 A JP2020550176 A JP 2020550176A JP 2021518384 A5 JP2021518384 A5 JP 2021518384A5
Authority
JP
Japan
Prior art keywords
triazole
dihydro
aminomethyl
fluoropropane
methyl
Prior art date
Application number
JP2020550176A
Other languages
English (en)
Japanese (ja)
Other versions
JP7383627B2 (ja
JPWO2019180646A5 (https=
JP2021518384A (ja
Filing date
Publication date
Priority claimed from KR1020180032548A external-priority patent/KR20190110736A/ko
Application filed filed Critical
Publication of JP2021518384A publication Critical patent/JP2021518384A/ja
Publication of JP2021518384A5 publication Critical patent/JP2021518384A5/ja
Publication of JPWO2019180646A5 publication Critical patent/JPWO2019180646A5/ja
Priority to JP2023128580A priority Critical patent/JP2023145748A/ja
Application granted granted Critical
Publication of JP7383627B2 publication Critical patent/JP7383627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550176A 2018-03-21 2019-03-20 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物 Active JP7383627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023128580A JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0032548 2018-03-21
KR1020180032548A KR20190110736A (ko) 2018-03-21 2018-03-21 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
PCT/IB2019/052278 WO2019180646A1 (en) 2018-03-21 2019-03-20 Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023128580A Division JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Publications (4)

Publication Number Publication Date
JP2021518384A JP2021518384A (ja) 2021-08-02
JP2021518384A5 true JP2021518384A5 (https=) 2022-03-11
JPWO2019180646A5 JPWO2019180646A5 (https=) 2022-03-11
JP7383627B2 JP7383627B2 (ja) 2023-11-20

Family

ID=67986894

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020550176A Active JP7383627B2 (ja) 2018-03-21 2019-03-20 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物
JP2023128580A Pending JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023128580A Pending JP2023145748A (ja) 2018-03-21 2023-08-07 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物

Country Status (10)

Country Link
US (2) US10995086B2 (https=)
EP (1) EP3768675B1 (https=)
JP (2) JP7383627B2 (https=)
KR (2) KR20190110736A (https=)
CN (1) CN111886233B (https=)
AR (1) AR115007A1 (https=)
AU (1) AU2019237344B2 (https=)
CA (1) CA3093057A1 (https=)
TW (1) TWI803600B (https=)
WO (1) WO2019180646A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20200004036A (ko) * 2018-07-03 2020-01-13 주식회사유한양행 (e)-(2-(클로로메틸)-3-플루오로알릴)카바메이트 유도체의 제조방법
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
BR112021013429A2 (pt) 2019-01-11 2021-10-19 Nanjing Transthera Biosciences Co., Ltd. Composto, composição farmacêutica, e, uso do composto
KR20220145981A (ko) * 2021-04-22 2022-11-01 주식회사유한양행 트리아졸론, 테트라졸론, 및 이미다졸론, 또는 그의 염, 및 그를 포함하는 제약 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (de) 1977-06-03 1978-12-14 Hoechst Ag 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung
US20050096360A1 (en) 2003-08-08 2005-05-05 Salter-Cid Luisa M. Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (ko) 2003-08-12 2006-04-25 한국화학연구원 불소화 비닐 에테르 측쇄기를 갖는 아졸계 살균제 화합물및 그의 제조방법
KR20060135781A (ko) * 2004-02-25 2006-12-29 라 졸라 파마슈티칼 컴파니 질병의 치료를 위한 아민 및 아미드
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
BRPI0809617A2 (pt) * 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
JP2011504485A (ja) 2007-11-21 2011-02-10 ファーマクシス リミテッド Ssao/vap−1のハロアリルアミン阻害剤およびその用途
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3438087A1 (en) 2012-05-02 2019-02-06 Boehringer Ingelheim International GmbH Substituted 3-haloallylamine inhibitors of ssao and uses thereof
BR112015026631A2 (pt) * 2013-04-25 2017-07-25 Yuhan Corp compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3230277B1 (en) 2014-12-11 2019-09-18 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
JP6849197B2 (ja) 2016-02-12 2021-03-24 ファーマクシス リミテッド リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用
WO2017191112A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
BR112019005930A2 (pt) 2016-10-19 2019-06-11 Boehringer Ingelheim Int combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
US20200069648A1 (en) 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
US20200087248A1 (en) 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
AU2018287777B2 (en) 2017-06-20 2020-05-21 Shandong Danhong Pharmaceutical Co., Ltd. SSAO inhibitor
CN109810041B (zh) 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
KR20190110740A (ko) 2018-03-21 2019-10-01 주식회사유한양행 신규의 아릴 또는 헤테로아릴 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20190110736A (ko) * 2018-03-21 2019-10-01 주식회사유한양행 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN110938059A (zh) 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
WO2020063854A1 (zh) 2018-09-27 2020-04-02 南京明德新药研发有限公司 作为vap-1抑制剂的喹啉类衍生物
CN113164454A (zh) 2018-09-28 2021-07-23 奥克塞拉有限公司 Vap-1的抑制剂
MX2021003731A (es) 2018-09-28 2021-08-05 Acucela Inc Inhibidores de vap-1.
CN112789277B (zh) 2018-10-22 2022-11-04 广东东阳光药业有限公司 胍类衍生物及其用途
AU2019365213A1 (en) 2018-10-24 2021-06-03 Metacrine, Inc. SSAO inhibitors and uses thereof
TWI835945B (zh) 2018-12-14 2024-03-21 南韓商柳韓洋行股份有限公司 3,3-二氟烯丙胺化物或其鹽及包含彼的醫藥組合物
TW202039486A (zh) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 三唑并吡啶-3-酮化物或其鹽及包含彼之醫藥組合物
BR112021013429A2 (pt) 2019-01-11 2021-10-19 Nanjing Transthera Biosciences Co., Ltd. Composto, composição farmacêutica, e, uso do composto

Similar Documents

Publication Publication Date Title
JP2021518384A5 (https=)
IL283539B2 (en) 3,3-Difluoroallylamines or their salts and pharmaceutical preparations containing them
JP6339595B2 (ja) 炎症性障害の治療のための化合物及びその医薬組成物
ES2642586T3 (es) Compuestos heterocíclicos condensados como moduladores de canales iónicos
CN105339370B (zh) 用于治疗炎症性疾病的化合物和及其药物组合物
CN116547279A (zh) 杂环glp-1激动剂
CN111556871B (zh) 作为PDE1抑制剂的1H-吡唑并[4,3-b]吡啶
JP2020514267A5 (https=)
JP2022502424A5 (https=)
JP2021518377A5 (https=)
JP2025504508A (ja) ヘテロ環式glp-1アゴニスト
JP2025510741A (ja) ヘテロ環式glp-1アゴニスト
JP2014532626A5 (https=)
CN111886233B (zh) 三唑酮衍生物或其盐以及包含其的药物组合物
JP2020512289A5 (https=)
JP2021501805A5 (https=)
TW202140496A (zh) 經取代嘧啶及其用途
US9890171B2 (en) Aldosterone synthase inhibitors
JPWO2019180646A5 (https=)
TW202519220A (zh) 化合物、組合物及方法
TW202521528A (zh) 化合物、組合物及方法
JP2024510487A (ja) 新規なチアジアゾロピリミドン誘導体
JP2021527099A (ja) Gaba a alpha5 pamとしての新規イソオキサゾリルエーテル誘導体
CN116171280A (zh) 酪蛋白激酶1δ调节剂
JPWO2020065613A5 (https=)